Skip to content

Study · Not a test of the peptide alone · 1987

1 result

Intracerebroventricular injection of cholecystokinin octapeptide elevates plasma prolactin levels through stimulation of vasoactive intestinal polypeptide.

Tanimoto K, Tamminga CA, Chase TN, Nilaver G

Endocrinology1 Jul 1987Cited by 8 (Europe PMC)

PMID3297634 (opens in a new tab)DOI10.1210/endo-121-1-127 (opens in a new tab)PepBankPUB-03297634
Source linkPubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

  1. 01AnimalNot a test of Vasoactive intestinal peptide (VIP, aviptadil) aloneAnimal study (in vivo)Mechanism

    In male rats, a VIP antiserum given intracerebroventricularly substantially antagonized the rise in plasma prolactin produced by intracerebroventricular CCK-8.

    In plain wordsIn rats, blocking VIP with an antiserum largely stopped the prolactin rise that CCK-8 caused.

    Peptide
    Vasoactive intestinal peptide (VIP, aviptadil)
    Outcome
    DecreaseCCK-8-induced PRL increase with VIP antiserum
    Study

    ratn: not reported in source

    Freely moving male rats
    Comparator
    icv CCK-8 without antiserum
    Outcome group
    Pituitary hormones · Endocrine and hormones

    Source sentences

    Summary
    Finally, the elevation in plasma PRL levels produced by icv CCK-8 was substantially antagonized by vasoactive intestinal polypeptide antiserum (1:3; 10 microliter/rat, icv).
    1 context sentence
    Summary · context
    We investigated the effect of cholecystokinin octapeptide (CCK-8) on plasma PRL levels in freely moving male rats.

    In this study, Vasoactive intestinal peptide (VIP, aviptadil) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Vasoactive intestinal peptide (VIP, aviptadil).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 12:41 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.